Medilink therapeutics announces a multi-target tmalin® adc technology platform license agreement with biontech, expanding their global strategic partnership

Suzhou, china, may 26, 2024 /prnewswire/ -- medilink therapeutics (suzhou) co., ltd. ("medilink"), a clinical-stage biotech company, today announces a new strategic collaboration with biontech se (nasdaq: bntx, "biontech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which biontech will receive an exclusive option to an exclusive global license to apply medilink's tmalin® antibody-drug conjugate (adc) platform, for several novel targets chosen by biontech.
BNTX Ratings Summary
BNTX Quant Ranking